Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Unverified reports of a U.S. strike in the Caribbean, with provided links leading to unrelated content.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Unverified reports of a U.S. strike in the Caribbean, with provided links leading to unrelated content.